WARF: P07377US02

  • Assigned to WARF as biological material.

Safer Ebola Virus and Vaccines


Yoshihiro Kawaoka, Peter Halfmann, Jin Hyun Kim

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing replication-incompetent filovirus that is safer to handle and can be used to make new vaccines.
OVERVIEWEbola is the deadliest virus on earth. It has caused death in 90 percent of cases during some outbreaks, afflicting human and great ape populations in tropical Africa. The virus is highly contagious in aerosol form and ranks with anthrax as a potentially devastating bioweapon.

While the first Ebola vaccine is under development, studying the virus entails stringent (biosafety level-4) containment protocols exceeding the resources of most laboratories. Surrogates have been utilized in place of the authentic virus, but this has hampered basic research with Ebolaviruses as well as the development of vaccines and large-scale screening for effective antivirals.

Producing new Ebola vaccines and expanding research will require genetically manipulating a safer form of the virus.
THE INVENTIONUW–Madison researchers have developed recombinant, biologically-contained Ebola ‘ΔVP30’ virus for use as a vaccine and research tool. The infectious virus cannot spread because it is made to lack a gene essential for transcription.

Specifically, sequences encoding the protein VP30 are deleted from the virus genome, making it unable to replicate. Prepared and administered pharmaceutically, the modified virus evokes an antibody response against Ebola virus glycoprotein, GP. Selectable markers, reporters and other heterologous sequences can be inserted into the genome.
  • Producing vaccines for Ebola and other diseases
  • Viral mutagenesis studies
  • Drug screening
  • Gene therapy vectors
  • Vaccine/virus is genetically stable and safe.
  • Resembles wild-type virus in life cycle, morphology and growth
  • Can be grown to reasonably high titers in helper cells
  • Can be handled outside a biosafety level-4 environment
STAGE OF DEVELOPMENTVaccine ΔVP30 provided 100 percent protection in mice exposed to Ebola virus. It generated antibody response to the viral glycoprotein, GP, as well as T-cell response to viral nucleocapsid protein, NP.
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.